Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats

© 2016 by The North American Menopause Society. Objective: Cardiac function was markedly compromised in obese insulin-resistant and estrogen-deprived rats. Metformin and dipeptidyl peptidase-4 inhibitor (vildagliptin) were reported to improve cardiac function in insulinresistant rats. Their effects...

Full description

Saved in:
Bibliographic Details
Main Authors: Sivasinprasasn S., Sa-Nguanmoo P., Pongkan W., Pratchayasakul W., Chattipakorn S., Chattipakorn N.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975484640&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41711
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-41711
record_format dspace
spelling th-cmuir.6653943832-417112017-09-28T04:22:59Z Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats Sivasinprasasn S. Sa-Nguanmoo P. Pongkan W. Pratchayasakul W. Chattipakorn S. Chattipakorn N. © 2016 by The North American Menopause Society. Objective: Cardiac function was markedly compromised in obese insulin-resistant and estrogen-deprived rats. Metformin and dipeptidyl peptidase-4 inhibitor (vildagliptin) were reported to improve cardiac function in insulinresistant rats. Their effects on the heart under estrogen-deprived conditions are, however, unknown. Therefore, the effects of metformin, vildagliptin, and estrogen on the cardiac function in estrogen-deprived insulin-resistant female rats were investigated. Methods: Bilateral ovariectomized female rats (n=48) were divided to be fed with either a normal diet (ND) or a high-fat diet (HFD) for 12 weeks. Then, both ND- and HFD-fed groups were subdivided to receive a vehicle, estrogen (50mg/kg), metformin (30 mg/kg), or vildagliptin (3 mg/kg) for 4 weeks (n=6/group). Heart rate variability, echocardiography, metabolic and biochemical parameters, cardiac function, and mitochondrial function were determined. Sham-operated female rats (n=6) were used as a control. Results: Both ND- and HFD-fed ovariectomized rats developed insulin resistance, depressed heart rate variability, and decreased cardiac contractility. Although treatment with metformin, vildagliptin, and estrogen improved metabolic status and cardiac function, only estrogen and vildagliptin improved diastolic blood pressure and left ventricular ±dP/dt, and also reduced mitochondrial impairment, apoptosis, and oxidative stress in HD-fed ovariectomized rats. Conclusions: Treatment with estrogen and vildagliptin provided more beneficial effects in the inhibition of oxidative stress, apoptosis, and cardiac mitochondrial dysfunction, and preserved cardiac contractile performance in estrogen-deprived insulin-resistant female rats. 2017-09-28T04:22:59Z 2017-09-28T04:22:59Z 2016-07-26 Journal 10723714 2-s2.0-84975484640 10.1097/GME.0000000000000640 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975484640&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41711
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
description © 2016 by The North American Menopause Society. Objective: Cardiac function was markedly compromised in obese insulin-resistant and estrogen-deprived rats. Metformin and dipeptidyl peptidase-4 inhibitor (vildagliptin) were reported to improve cardiac function in insulinresistant rats. Their effects on the heart under estrogen-deprived conditions are, however, unknown. Therefore, the effects of metformin, vildagliptin, and estrogen on the cardiac function in estrogen-deprived insulin-resistant female rats were investigated. Methods: Bilateral ovariectomized female rats (n=48) were divided to be fed with either a normal diet (ND) or a high-fat diet (HFD) for 12 weeks. Then, both ND- and HFD-fed groups were subdivided to receive a vehicle, estrogen (50mg/kg), metformin (30 mg/kg), or vildagliptin (3 mg/kg) for 4 weeks (n=6/group). Heart rate variability, echocardiography, metabolic and biochemical parameters, cardiac function, and mitochondrial function were determined. Sham-operated female rats (n=6) were used as a control. Results: Both ND- and HFD-fed ovariectomized rats developed insulin resistance, depressed heart rate variability, and decreased cardiac contractility. Although treatment with metformin, vildagliptin, and estrogen improved metabolic status and cardiac function, only estrogen and vildagliptin improved diastolic blood pressure and left ventricular ±dP/dt, and also reduced mitochondrial impairment, apoptosis, and oxidative stress in HD-fed ovariectomized rats. Conclusions: Treatment with estrogen and vildagliptin provided more beneficial effects in the inhibition of oxidative stress, apoptosis, and cardiac mitochondrial dysfunction, and preserved cardiac contractile performance in estrogen-deprived insulin-resistant female rats.
format Journal
author Sivasinprasasn S.
Sa-Nguanmoo P.
Pongkan W.
Pratchayasakul W.
Chattipakorn S.
Chattipakorn N.
spellingShingle Sivasinprasasn S.
Sa-Nguanmoo P.
Pongkan W.
Pratchayasakul W.
Chattipakorn S.
Chattipakorn N.
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
author_facet Sivasinprasasn S.
Sa-Nguanmoo P.
Pongkan W.
Pratchayasakul W.
Chattipakorn S.
Chattipakorn N.
author_sort Sivasinprasasn S.
title Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
title_short Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
title_full Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
title_fullStr Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
title_full_unstemmed Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
title_sort estrogen and dpp4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats
publishDate 2017
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975484640&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/41711
_version_ 1681422052602413056